Sirnaomics raised the money to advance a pipeline of drug candidates underpinned by its polypeptide nanoparticle (PNP) and GalNAc (N-Acetylgalactosamine) technology platforms (Fig. 1). PNP offers ...

RNAi therapeutics have shown great success with multiple US Food and Drug Administration (FDA)-approved products involving N-acetyl galactosamine (GalNAc)-conjugated siRNAs to treat liver-targeted ...

“Lepodisiran is attached to a compound known as N-acetylgalactosamine, or GalNAc, that is picked up by the hepatocytes and then delivers lepodisiran into the cell, where it forms an RNA-induced ...